Compare ADPT & UTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | UTI |
|---|---|---|
| Founded | 2009 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2019 | 2003 |
| Metric | ADPT | UTI |
|---|---|---|
| Price | $15.14 | $41.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $17.78 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 1.7M | 1.3M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | 50.67 |
| EPS | N/A | ★ 0.24 |
| Revenue | $276,976,000.00 | ★ $835,616,000.00 |
| Revenue This Year | $3.98 | $10.15 |
| Revenue Next Year | $22.72 | $8.32 |
| P/E Ratio | ★ N/A | $172.46 |
| Revenue Growth | ★ 54.77 | 14.05 |
| 52 Week Low | $9.78 | $21.29 |
| 52 Week High | $20.76 | $41.92 |
| Indicator | ADPT | UTI |
|---|---|---|
| Relative Strength Index (RSI) | 61.94 | 59.73 |
| Support Level | $14.87 | $34.84 |
| Resistance Level | $15.27 | N/A |
| Average True Range (ATR) | 0.64 | 2.30 |
| MACD | 0.23 | 0.23 |
| Stochastic Oscillator | 88.33 | 93.81 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Universal Technical Institute Inc is an educational institution. It provides undergraduate degree, as well as certificate programs for technicians in the automotive, diesel, collision repair, motorcycle and marine fields. The company's reportable segment which includes Universal Technical Institute (UTI) and Concorde Career Colleges, Corporate. Majority of the revenue is generated from UTI segment which provides different kinds of degree and non-degree transportation and skilled trades technical training programs under brands such as Universal Technical Institute, Motorcycle Mechanics Institute, Marine Mechanics Institute and others. It also provides dealer technician training or instructor staffing services to manufacturers.